For the longest time, drug research and development techniques have had their nuances. For instance, in the past, the medical treatments, despite consisting of medications, offered a lesser guarantee with a situation of if-and-then being more prevalent. However, the emergence of artificial intelligence (AI) algorithms provides current medical procedures with advanced capabilities. It has become sufficiently easier to predict the protein folding process based on amino acid sequences.
The current AI scenario offers algorithms that are highly sophisticated with a vast sea of big data to be explored. The major problem in exploring data is aggregating it after obtaining the data from wide-ranging silos. This is the main problem-solving statement of SOPHiA GENETICS. SOPHiA has its headquarters in Lausanne, Switzerland, and in Boston, United States. Seven years ago, in 2014, the company launched its first software application on its platform. This application enabled the analysis of genomic sequencing data targeting cancer diagnosis.
These profiles were analyzed for 780 hospitals, laboratory, and biopharma clients. However, only 365 of those have been able to generate revenue in the last 12 months. SOPHiA Genetics’ platform is designed on a decentralized model, which allows them to deliver analytics solutions to customer’s sites. It is the opposite of a centralized model wherein the samples are required to be sent to a central location.